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Abstract The purpose of this randomized, double-blind parallel group study was to compare the safety, tolerability
and acceptability of Easyhalers and Turbuhalers dry powder inhalers for the delivery of budesonide 800 mgday1 in
adult asthmatic patients who had already been treated with inhaled corticosteroids for at least 6 months prior to the
study. Additionally the efficacy of the productswas evaluated.Themain objectivewas to evaluate the systemic safetyof
budesonide inhaled from Easyhalers (Gionas Easyhalers,Orion Pharma, Finland) as determined by serum and urine
cortisol measurements.The secondary objective was to compare the tolerability, acceptability and efficacy of the two
devices in the administration of budesonide. After a 2-week run-in period (baseline), patientswere randomized on a 2:1
basis to receive budesonide from Easyhalers (n=103) or fromTurbuhalers (Pulmicorts Turbuhalers, AstraZeneca,
Sweden) (n=58) 200 mgdose1, two inhalations twice daily for12 weeks.There was no statistically significant change in
morningserumcortisolvalues frombaselinetotheendoftreatmentineithergroup.Urine freecortisolandurinecortisol/
creatinine ratio increased from baseline in both groups.There were no significant differences between the groups in
terms ofmorning serumcortisol, urine cortisol, adverse events orefficacy variables, but Easyhalerswasgenerally con-
sideredmore acceptable to the patients. In conclusion, at 800 mgday1,Gionas Easyhalers is as safe and efficacious as
Pulmicorts Turbuhalers in adult asthmatic patients previously treated with corticosteroids, but more acceptable to
patients.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1261, available online athttp://www.idealibrary.comon
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Airway in£ammation is considered to be the cause of the
symptoms andphysiological abnormalities of asthma and
it should be the primary target of asthma treatment (1).
The in£ammation is characterised by the presence of in-
£ammatory cells such as eosinophils and neutrophils (2).
Corticosteroids have been shown to suppress the air-
way in£ammation and bronchial hyperresponsiveness
associated with asthma, and are now recommended
as ¢rst-line therapy for the treatment of asthmatic
patients (1).
Clinically, the most important systemic adverse drug
reactions (ADRs) of inhaled corticosteroids are hypotha-Received 20 July 2001and accepted in revised form 2 November 2001.
Correspondence shouldbe addressed to:KaisaMariHHmHlHinen,Orion
Pharma, Po Box1780, 70701Kuopio, Finland.Fax: +35810 4286 444; E-
mail: kaisa.hamalainen@orionpharma.comlamic^pituitary^adrenal (HPA) axis suppression (3^5),
increased bone turnover (6) and impaired glucose and li-
pid metabolism (7). However, these e¡ects are asso-
ciated with high-dose therapy (41000mgday1) (8,9).
At doses of up to 400mgday1 in children, and up to
800mgday1 in adults, inhaled corticosteroids have been
shown to have minimal systemic e¡ects, irrespective of
preparation (10).The therapeutic goal should be to opti-
mize asthma control with minimal systemic e¡ects or
ADRs by adjusting the dose of inhaled corticosteroid ac-
cording to individual requirements.
It is generally acknowledged that the inhaler is a key
element in determining the e⁄cacy, adverse event pro-
¢le, and safety of asthma therapy (11). Pressurized me-
tered-dose inhalers (pMDIs) are currently the most
common forms of delivery device for inhaled therapy
in most European countries (12). However, these
devices are associated with a number of problems,
222 RESPIRATORYMEDICINEnotably di⁄culty in achieving the level of coordination ne-
cessary for correct dose delivery, leading to reduced ef-
fectiveness and poor compliance. Furthermore, most
pMDIs contain ozone-depleting chloro£uorocarbons
(CFCs) as propellants.Hence, these are being phased out
to meet an imminent ban on the use of CFCs (12). Non-
CFC pMDIs are now available. These pMDIs have chlor-
ine-free hydro£uoroalkane (HFA) as a propellant (13).
In order to overcome these problems, breath-actu-
ated powder inhalers were developed, and one of the
¢rst was Turbuhalers (AstraZeneca, Sweden). Easyha-
lers is a new generation breath-actuated multidose
powder inhaler developed by Orion Pharma in Finland,
and is currently available for the delivery of salbutamol
and beclometasone dipropionate (BDP).
In the present study, primarily the safety, tolerability
and acceptability of Easyhalers and Turbuhalers for
the delivery of budesonide 800mgday1were compared
in adult asthmatic patientswho had alreadybeen treated
with inhaled corticosteroids. Additionally, the e⁄cacy of
the products was evaluated. The main objective of the
study was to evaluate the systemic safety of budesonide
inhaled from Easyhalers, as determined by serum and
urine cortisol measurements. Secondary objectives
were to compare the tolerability, acceptability and e⁄-
cacy of the two devices. In addition, thebronchial in£am-
mation and the e¡ect of budesonide on it was studied in




Non-smoking male and female asthma outpatients aged
18^70 years were recruited from 14 centres in Finland.
All patients were required to have been diagnosed with
bronchial asthma (ATS criteria) and to have used inhaled
BDP or budesonide on a regular daily basis over at least
the previous 6 months. For the 4 weeks prior to the
study, they were also required to have inhaled BDP or
budesonide at a dose level of 800^1000mgday1. In order
to be included in the study, patients had to have a forced
expiratory volume in1sec (FEV1)460% of the predicted
value before taking a bronchodilator, measured within 4
weeks before the beginning of the run-in period or on
the ¢rst visit (14).
Patients were excluded from the study if they had
known hypersensitivity to either budesonide or lactose,
or any exacerbation of asthma or respiratory infection
during the previous 4 weeks. Ex-smokers could be in-
cluded if they had stopped smoking at least 6 months
prior to the study. Patients with a manifest heart condi-
tion (NYHAClass II^IV), severe hepatic or renal disease,
inadequately controlled hyperthyroidism or diabetes
mellitus (type I or II) were excluded from the study, aswere women who were pregnant, breast-feeding or fer-
tile and without reliable contraception. Patients were
not allowed to have received oral corticosteroids or
beta-blockers during the previous 4 weeks, nor could
they have any regular treatment with anticholinergics,
theophyllines, oral or inhaled cromoglycate, nedocromil,
leukotriene antagonists, short- or long-acting antihista-
mines, or long-acting sympathomimetics during study
entry. Patients who had previously participated in this
study, or in any other clinical drug study within 8 weeks
of this one, were also excluded.
Study design
This multicentre study was carried out according to a
randomized, double-blind, double-dummy, parallel-
group design. After a 2-week run-in period, patients
were randomized on a 2:1basis to receive eitherbudeso-
nide from Easyhalers (Gionas Easyhalers, Orion Phar-
ma, Finland) or budesonide from Turbuhalers
(Pulmicorts Turbuhaler, AstraZeneca, Sweden) for 12
weeks (Fig. 1). Both devices delivered budesonide at a
dose of 200mg inhalation1and patients were instructed
to perform two inhalations twice daily at 6^8 a.m. and
7^9 p.m., giving a total budesonide dose of 800mgday1.
Concurrently, with inhalations of budesonide from Easy-
halers, the patient inhaled placebo fromTurbuhalers or
vice versa. Patients were instructed to rinse theirmouth
withwater and spit it out after each inhalation.
Patients were permitted to use salbutamol inhalation
powder (Buventol Easyhalers100mgdose1,Orion Phar-
ma, Finland) as rescue medication. If necessary, they
could also take a1-weekcourse of an oral corticosteroid
(prednisolone 30^40mgday1) or one course of an anti-
biotic, but could bewithdrawn from the study if they ex-
ceeded these limits. Home peak expiratory £ow (PEF)
measurements were carried out using a standard Mini-
WrightTM Peak Flow Meter (Clement Clarke Interna-
tional Ltd, England) before inhaling the drug and prefer-
ably, at least 6h after any salbutamol inhalation.
After therun-inperiod and after the 6th,10th and14th
study weeks, on the evening before the clinic visits, pa-
tients were asked to take the study drug (preferably at 8
p.m.) after they had emptied their bladder. They then
started collecting all overnight urine for10h.No further
corticosteroids were taken until completion of the fol-
low-up visit the next morning.Use of salbutamol inhala-
tionwas to be avoided for 8h before the follow-up visits.
Blood samples for measuring morning serum cortisol
concentrations were taken after overnight fasting at
the end of the run-in period and at the end of study
weeks 6, 10 and 14, preferably at the same time at each
visit (7^9 a.m.).
Sputum inductions for measuring eosinophils, neutro-
phils, macrophages, eosinophil cationic proteins (ECP)
Beginning of the study
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Blood chemistry X X
X
Adverse event inquiry and observation X X X X
Induced sputum X X
FIG. 1. Studydesign.
GIONAsEASYHALERs VS.PULMICORTs TURBUHALERs 223and myeloperoxidase (MPO) were performed in the pa-
tients of two study centers after run-in period and at the
end of the study.
Compliance was determined by patient diary records
of corticosteroid use, and return of both used and un-
used study drugs to the study centre at the end of the
treatment period.
All study documents were reviewed and approved by
the Ethics Committees of the participating hospitals. All
patients were required to givewritten informed consent
and the study was conducted according to the principles
of the currentrevision of theDeclaration ofHelsinki (15).
Outcome variables
The primary safety variablewas the systemic bioactivity
of budesonide, which was determined by measuring sin-
gle morning (7^9 a.m.) serum cortisol (normal reference
range190^700nmol l1) andurine free cortisol alone and
corrected by creatinine excretion [urine cortisol/creati-
nine (UCC) ratio].
All adverse events, whether considered to be drug-re-
lated or not, were recorded in the patients’ diaries, in-
cluding type and severity (with a daily score of 0^3).
Patients were speci¢cally asked to record and score any
occurrence of hoarseness and sore throat, sum scores
for which were calculated for the run-in period andevery 4weeks during treatment.During all follow-upvis-
its, the presence of oropharyngeal candidiasis was deter-
minedby visual examination and, if therewas evidence of
infection, by oropharyngeal swabs. The number of
courses of antimycotic treatment prescribed was also
recorded.
Patients evaluated the acceptability of the devices at
the last follow-up visit by use of a questionnaire on hand-
ling and ease of use, and a visual analogue scale (VAS)
score for overall opinion of the devices (ranging from ex-
tremely bad to extremely good).
The primary e⁄cacy variables were mean morning
and evening home PEF values, determined for the run-in
period (weeks 1^2) and for weeks 3^4, 7^8 and 11^14.
Secondary e⁄cacy variables included spirometry at the
study site [FEV1 and forced vital capacity (FVC)]; diurnal
variability in PEF, expressed as [(highestlowest)/high-
est100% per day]; number of beta2-agonist inhalations
during run-in and for each 4-week treatment period
thereafter; and severity sum scores for day- and night-
time asthma symptoms (dyspnoea, wheezing and cough,
where 0=no symptoms,1=mild, 2=moderate and 3=se-
vere), calculated for the run-in period and every 4weeks
thereafter.
In addition, at two of the study centres, the severity of
bronchial in£ammation was assessed bymeasuring eosi-
nophils, neutrophils, ECP and MPO concentrations
(mgl1 in each case) in induced sputum after the run-in
224 RESPIRATORYMEDICINEperiod and after the treatment period. The details of
sputum induction and analysis have been reported ear-
lier (16). In£ammatory cells in smears were examined on
a scale from 0 to 4. ECP and MPO were measured from
the supernatant.The reference ranges for total ECP and
MPO were taken as o2500mgl1 and o1200mgl1,
respectively.
Statistical analysis
The main aim of the study was to evaluate the safety of
inhaled budesonide 800mgday1. The ¢rst hypothesis
was that therewouldbeno signi¢cantchange inmorning
serum cortisol in the Easyhalers group from the end of
the run-in period (baseline) to the end of the study.The
secondhypothesiswas that therewouldbeno signi¢cant
di¡erence between treatment groups in morning serum
cortisol during the study period, as assessed from indivi-
dual measurements on follow-up visits. The secondary
aim of the study was to collect evidence about the ac-
ceptability, tolerability and e⁄cacy of Gionas Easyha-
lers compared to Pulmicorts Turbuhalers. A two-
sided P-value of less than 5% was considered statistically
signi¢cant.
For analyses concerning safety and tolerability, all
available data were utilized. Conclusions concerning the
safety and e⁄cacyof the treatmentswerebased primar-
ily on ITTanalyses.
Changes in morning serum cortisol, urine free corti-
sol and UCC ratio from baseline to the last visit were
analysed using theWilcoxon one-sample test. Between-
treatment comparisons in these variables were
performed using analysis of covariance with baseline
measured as a covariate.
All adverse events were classi¢ed by severity and by
causal relationship to study treatment.The di¡erence in
the number of oropharyngeal Candida infections was
analysed only descriptively.
Improvement in morning and evening PEF was ana-
lysed separately for both treatmentgroups using an ana-
lysis of variance (ANOVA) model.Mean values for the 2-
week run-in period and subsequent 4-week treatment
periods for each treatmentwere calculated.Thesevalues
were analysed using repeated measurement analysis of
covariance. The main interest lay on the comparison at
treatment weeks 9^12, but also the overall treatment
di¡erence, including the whole treatment period, was
examined. Spirometric measurementswere analysed ac-
cordingly, but instead of periodwise means actual values
were used. Sum scores for asthma symptoms and sym-
pathomimetic inhalations were analysed using the
Mann^Whitney U-test.
Data of sputum induction are expressed as means.
Some values for in£ammatory markers lay beneath low-
est standard values.Results of comparisons between thetwo groups were analysed using Mann^Whitney U-test
or the chi-squared test, as appropriate.Two-tailed P-va-
lues below 0?05 were considered to indicate signi¢cance.
The estimated sample size was based on the planned
treatment randomization ratio (2:1 for Easyhalers:Tur-
buhalers), prede¢ned clinically signi¢cant di¡erence of
50nmol l1 and assumed sample standard deviation of
150nmol l1 in morning serum cortisol. The signi¢cance
level in a two-sided test was set at 5% and the sample
size was calculated to give a power of 0?9.This yielded a
required sample size of 97 in the Easyhalers group (17).
However, in order to allow for some premature discon-
tinuations during the study period, target populations of




A total of 161 patients were enrolled in the study, of
whom103 were randomised to the Gionas Easyhalers
group and 58 to the Pulmicorts Turbuhalers group (Ta-
ble 1). The distribution of female subjects di¡ered be-
tween the groups (58% in the Easyhalers group and
74% in theTurbuhalers group), which accounted for the
observed di¡erences in terms of cortisol, PEF and spiro-
metry values. In addition to asthma, a baseline disease
was reported by 60% of patients in Easyhalers group
and 72% in Turbuhalers group, the most common one
being rhinitis. The most common baseline symptoms
were headache, dysphonia and coughing and they oc-
curred equally in both groups.
One hundred and forty-six patients completed the
study: 91 in the Easyhalers group and 55 in theTurbuha-
lers group. Reasons for premature discontinuation in
each group are shown inTable 2.
Compliance
According to the daily diaries of all patients who com-
pleted the study, themean (SD) percentage of study drug
usagewas 98 (5) % in the Easyhalers group and 98 (3) %
in theTurbuhalers group.
Safety
In the Easyhalers group, morning serum cortisol values
remained almost unchanged from baseline (end of the
run-in period) until the end of the 12-week treatment
period [Fig. 2(a)]. In theTurbuhalers group, there was a
slight decrease inmorning serum cortisol values, but the
di¡erence was not statistically signi¢cant between the
groups. Five patients (two in the Easyhalers group and
three in theTurbuhalers group) had onemorning serum
cortisol readingo190nmol l1, whichwas considered to
TABLE 1. Demographic andbaselinepatientinformation.Values aremeans (SD) exceptfor sex, numberof atopics, numberwith
symptoms, andnumberwith disease
Parameter Easyhalersn=103 Turbuhalersn=58
Age, years 46 (14) 47 (13)
Female/male 60/43 43/15
Height, cm 170 (9) 166 (7)
Weight, kg 75 (14) 72 (12)
Number (%) of atopics 49 (47?6) 31 (53?4)
Duration of asthma symptoms, years 5 (7) 6 (7)
Number (%) with symptoms 58 (56?3) 35 (60?3)
Morning serumcortisol, nmoll1* 458 (176) 435 (157)
Urine free cortisolnmoll1* 74 (73) 60 (53)
UCCratio, nmolmmol1* 8 (10) 6 (3)
Morning PEF, lmin1 484 (91) 463 (82)
Evening PEF, lmin1 486 (92) 464 (82)
FEV1
Litres 3?07 (0?85) 2?87 (0?64)
% of predicted 86 (13) 89 (13)
Dose of inhaled steroids before the study, mgday1 816 (155) 817 (57)
*Values fromthemeasurements done at visit 2 (end of run-inperiod).
TABLE 2. Reasons for studydiscontinuation
Easyhalers Turbuhalers
Adverse event 1 F
Loss to follow-up 1 F
Protocolviolation 2 F
Unsatisfactoryresponse 3 1
Withdrawal of consent 1 1
Other 4 1
Total 12 (12%) 3 (5%)
GIONAsEASYHALERs VS.PULMICORTs TURBUHALERs 225be the lower limit of the normal reference value. In all
exceptonepatient (in theTurbuhalers group) serum cor-
tisol levelso190nmol l1were associated with a course
of an oral corticosteroid during the study.
Urine free cortisol values increased from baseline to
the end of the treatment period in both treatment
groups, but only in the Easyhalers groupwas the di¡er-
ence statistically signi¢cant (P=0?015). At the end of run-
in period urine free cortisol value was 73?6 (74) nmol l1
in the Easyhalers group and 60?1 (53) nmol l1 in the
Turbuhalers group. After 12 weeks of treatment urine
free cortisol value was 91?3 (92) nmol l1 and 67?5 (75)
nmol l1 in the Easyhalers group and in theTurbuhalers
group, respectively. A similar trend was observed for
UCC ratios [Fig. 2(b)].
During the ¢rstmonth of treatment thereweremore
adverse events in both treatmentgroups thanduring the
third month. Fifty-two adverse events (52%) were con-
sidered to be possibly, probably, or de¢nitely related tostudy drug in the Easyhalers group, and 31 (53%) were
considered to be possibly, or probably drug-related in
theTurbuhalers group, andmostweremild ormoderate
in nature (Table 3). In both treatment groups, mean
scores (% of theoretical maximum) for hoarseness re-
mained unchanged during the study and those for sore
throat increased slightly.Only one patient (in the Easyha-
lers group) discontinued the study due to an adverse
event (coughing andworsening of asthma).Three serious
adverse events (SAEs) occurred during the study: one
hospitalization for haemorrhoid surgery in the Easyha-
lers group; one hysterectomy for uterinemyoma in the
Turbuhalers group; and onepregnancy ending in sponta-
neous abortion in theTurbuhalers group.Thesewere all
considered to be unrelated to study drug by the investi-
gators and by the sponsor, except for the spontaneous
abortion, which was considered unlikely to be drug-re-
lated.
During treatment, the occurrence of oropharyngeal
candidiasis (8/103 in the Easyhalers group and 4/58 in
the Turbuhalers group), and the number of courses of
antimycotics prescribed (7/103 and 4/58 in each group,
respectively) were similar in both groups.
Acceptability
In four out of 10 questions, a majority of the patients
(450%) rated Easyhalers superior to Turbuhalers,
although more patients found Turbuhalers ‘handier to
carry’ (Fig. 3). In particular, with Easyhalers most pa-
tients found it easier to know when the drug had been
















































FIG. 2. (a) Mean (SD) morning serum cortisol concentrations (nmoll1) in the Easyhalers group (&; n=91^97) and in theTurbuha-
lersgroup (&; n=55^57). (b)Mean (7SEM)UCCratios (nmolmmol1) inthe Easyhalersgroup (&; n=91^97) andintheTurbuhalers
group (&; n=54^57).
TABLE 3. Number (%) of adverse events (considered to






Dysphonia 20 (20) 12 (21)
Pharyngitis 14 (14) 10 (17)
Candidiasis 8 (8) 4 (7)
Taste perversion 4 (4) F
Coughing 2 (2) F
Glossitis 1 (1) 1 (2)
Stomatitis 1 (1) F
Laryngitis 1 (1) 1 (2)
Asthma 1 (1) F
Drymouth F 1 (2)
Tooth disorder F 1 (2)
Adrenal insu⁄ciency F 1 (2)
Total 52 (52) 31 (53)
226 RESPIRATORYMEDICINEwhich device they would choose, 59% of patients said
they would choose Easyhalers, 29% Turbuhalers and
12% expressed no preference. The mean (SD) VAS score
for overall acceptability of the devices was signi¢cantlyhigher for Easyhalers compared withTurbuhalers: 74?9
(17) mmversus 64?3 (21) mm, respectively (Po0?0001).
E⁄cacy
Therewereno statistically signi¢cantdi¡erences inmean
morning PEF valuesbetween the treatmentgroups, with
no signi¢cant changes from baseline to the end of treat-
ment (Table 4).The overall adjusted treatmentdi¡erence
was1?5 lmin1 (95% CI from5?6 to 8?5).The results of
mean evening PEF values were in accordance with the
morning PEF results (Table 4).
Both FEV1and FVCvaluesremainedalmostunchanged
during the study in both treatment groups, with no sig-
ni¢cant di¡erences between the groups (Table 4).
The use of additional inhaled salbutamol during the
run-in and treatmentperiodswas low and similar inboth
groups.
The incidence of daytime asthma symptoms (dys-
pnoea, wheezing and cough) was similar in each group
and remained more or less unchanged throughout the
study. Night-time asthma symptoms also remained simi-
lar in the Easyhalers group but increased slightly from
run-in to treatment weeks 9^12 for all three symptoms
Questions













F = Easier to know how much drug is left
G = More pleasant in design
H = Handier to carry 
I = Easier to clean
J = Subject,s choice 
A = Easier in learning to use
B = Easier to use
C = Easier dosing
D =  Easier inhalation
E = Easier to know when the drug has been received
FIG. 3. Acceptabilityof the devices.Easyhalers,&;Turbuhalers,&; no di¡erence, 50%.
TABLE 4. Mean (SD)morning PEF values (lmin1),FEV1and FVCvalues (l) atthe endofrun-in and atthe endoftreatmentweek
12
Easyhalers Turbuhalers
End of run-in After week12 End of run-in After week12
Morning PEF 484 (85) 482 (85) 458 (80) 460 (82)
FEV1 3?04 (0?78) 3?00 (0?79) 2?85 (0?65) 2?87 (0?69)








FIG. 4. Eosinophils in sputum at baseline and after12 weeks of
treatment in the Easyhalers group and in the Turbuhalers
group.
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tistically signi¢cant di¡erences between the treatment
groups.
A total of 21patients underwent sputum induction for
analysis of in£ammatory markers. Most patients (13/21)had low amount of sputum eosinophils (scale 0^1, less
than 5%) at baseline. Sputum eosinophils in both groups
decreased signi¢cantly during the budesonide treatment
(P=0?02) (Fig. 4). There were no signi¢cant changes in
ECP and MPO values during the study and no di¡erence
between treatments studied.
DISCUSSION
It has previouslybeen reported thatmost of the bene¢ts
of inhaled corticosteroids are achieved within 3 months
of starting therapy (18).The duration of treatment peri-
od in this study was selected not only because of the
pharmacodynamics of budesonide, but also to obtain a
reliable picture of the safety, tolerability and acceptabil-
ity of the treatments studied. Pulmicorts Turbuhalers
was selected as the active control since its use and prop-
erties have beenwidely documented.
The uneven allocation of treatment (2:1 for Easyhaler-
s:Turbuhalers) was considered justi¢ed since the main
228 RESPIRATORYMEDICINEaim of the study was to analyse systemic bioactivity of
budesonide over the study period in the Easyhalers
group. The treatment groups were generally well
matched in terms of demographic data and asthma his-
tory except for a predominance of females in theTurbu-
halers group. This had an inevitable e¡ect on cortisol,
and lung function values, both at baseline and during
treatment, resulting in lower values in theTurbuhalers
group than in the Easyhalers group. It has been shown
that there is a correlation between lean body mass and
urinary creatinine excretion (19) and that total plasma
creatinine is an accuratemeasure of total striatedmuscle
mass (20). Also oestrogens can have in£uence on corti-
costeroid binding globulin and cortisol concentration
(21).Thus, di¡erence in female/male distribution can have
in£uence both on creatinine and cortisol concentration
and also cortisol/creatinine ratio, which may explain the
di¡erence at baseline found in the present study.
Most multicentre studies have used single morning
serum cortisolmeasurements as a practicalmeans of as-
sessingpotentialHPA axis suppression (22,23).However,
thismethod is relatively insensitive, since there ismarked
diurnal variation in serum or plasma cortisol levels.
Therefore, in this studyovernight (10 h) urinaryunbound
cortisol was also determined, since it has been shown to
be a more sensitive measure of HPA axis function
(24,25). Overnight collection of urine for determination
of urine free cortisol is also simple to carry out and has
been reported to be as sensitive as 24-h collection, par-
ticularly when corrected for creatinine (24).
The results showed that mean morning serum corti-
sol values remained relatively unchanged in the Easyha-
lers group and, although there was some decrease in
the Turbuhalers group, mean values were above
400nmol l1 in both groups after the run-in period and
after12 weeks of treatment. In addition, urine free corti-
sol values and UCC ratios increased in both groups dur-
ing treatment and the changes from baseline were
statistically signi¢cant in the Easyhalers group. Other
safety parameters did not di¡er signi¢cantly between
the treatmentgroups.Mostof the adverse events consid-
ered to have anypossible relationship to studydrugwere
mild ormoderate in nature and therewere no SAEs con-
sidered to be related to study drug.
There were no signi¢cant di¡erences between the
treatment groups in any of the e⁄cacy variables, which
remained largely unchanged during the study. This was
expected because all patients had used inhaled corticos-
teroids (800^1000mgday1of BDP or budesonide) for at
least 6 months prior to the study.
The analysis of induced sputum has become an ac-
ceptedmethod for assessing the degree of in£ammation
and has been reported to be useful in the evaluation of
asthma severity and the e¡ect of inhaled corticosteroid
treatment (26^28). Recent studies have demonstrated a
correlation between the markers of in£ammation used,ECP andMPO, and the clinical data (26^30).Thismethod
also has the advantage of being a non-invasive technique.
Markers of in£ammation in induced sputum varied be-
tween patients in both treatment groups. In most pa-
tients with asthma previously treated with inhaled
steroids, sputum eosinophils are low (30). However, un-
der controlled budesonide treatment eosinophils
decreased signi¢cantly. Both inhalers studied had
equal anti-in£ammatory e¡ects also on the basis of
sputum results.
Response to the acceptability questionnaire showed
that the majority of patients rated Easyhalers superior
to Turbuhalers. The proportion of patients who pre-
ferred Easyhaler (59%) is consistentwith a meta-analysis
from previous studies in which patients were asked
which device they would choose; Easyhalers, orTurbu-
halers (31). In addition, Easyhalers scored signi¢cantly
better thanTurbuhalers onVAS score for overall opinion
of the device.
CONCLUSIONS
Budesonide 800mgday1inhaled fromEasyhalers orTur-
buhalers did not suppress the activity of the HPA axis,
as determinedbymorning serumcortisol, urine free cor-
tisol and UCC ratio values. Both Easyhalers andTurbu-
halers were generally well tolerated for the delivery of
budesonide and therewere no signi¢cant di¡erences be-
tween the treatment groups in terms of adverse events.
There were also no signi¢cant between-treatment dif-
ferences for any of the e⁄cacy variables. However, the
majority of patients considered Easyhalersmore accep-
table than Turbuhalers. In conclusion, Gionas Easyha-
lers is as safe and e⁄cacious as Pulmicorts
Turbuhalers for the treatment of asthmatic patients
who have already been treated with corticosteroids,
with better patient acceptability.
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